Latest News — Page 29

Can health be a nation’s most strategic asset? 💡📈

EFPIA’s guest analysis reframes health spending as high-return investment—showing how targeted innovation and earlier care (notably for HER2+ breast cancer) can reduce disease-driven productivity losses, unlock trillions in GDP, and deliver up to $4 back per $1 spent. It also outlines HEOR methods and policy shifts needed to make health central to economic strategy.

Read the full article to explore the projections, methodology, and practical steps for policymakers and payers.

#SyenzaNews #HealthEconomics #oncology #healthcarepolicy #innovation

Can a targeted antibiotic help plug the gap against metallo‑β‑lactamase Gram‑negative infections?

Infarmed approved Emblaveo (aztreonam + avibactam) for hospital financing in Portugal as a focused option for MDR Gram‑negative infections—particularly metallo‑β‑lactamase producers—after the REVISIT phase‑3 trial showed comparable 28‑day cure and safety to meropenem ± colistina; confidential budget‑impact terms and restricted use support stewardship and SNS sustainability. 🛡️

Read the full report for the clinical details, economic analysis and the contract terms that shaped access.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

🚀 Ready for the latest advancements in triple-negative breast cancer treatment?

The breakthrough data from the ASCENT-03 trial reveals that sacituzumab govitecan significantly extends median progression-free survival to 9.7 months, showcasing promise for patients who can’t use PD-1/PD-L1 inhibitors. This innovative therapy might just redefine frontline strategies for this aggressive cancer type.

Curious about its impact on patient outcomes and survival rates? Dive into the full article to explore these cutting-edge findings!

#SyenzaNews #oncology #HealthcareInnovation

Could the FDA’s first interchangeable biosimilar to Perjeta unlock cheaper, more accessible HER2-positive breast cancer care? 🔬💊

Poherdy (pertuzumab-dpzb) matched Perjeta in rigorous analytical, PK, and clinical evaluations, supporting pharmacy-level substitution and equivalent use with trastuzumab-based regimens. This approval could lower patient costs, improve adherence, and shift market access and reimbursement dynamics for HER2 therapies.

Read the full analysis to see the data and market implications.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess #costeffectiveness

Could a once-daily single tablet change HIV care for people on complex regimens? 💊📈

Gilead’s Phase 3 ARTISTRY‑1 results show the investigational bictegravir/lenacapavir (BIC/LEN) single‑tablet regimen maintained virologic suppression at Week 48 with non‑inferior efficacy and a favorable tolerability profile in adults switching from multi‑tablet ART. This simplified STR could reduce pill burden, improve adherence, and strengthen value propositions for payers as regulatory submissions progress.

Read the full article to explore the trial design, safety data, and implications for patients and market access.

#SyenzaNews #clinicaltrials #pharmaceuticals #MarketAccess #costeffectiveness

Who pays for €2M one‑time gene therapies — and how do we balance innovation with equitable access? ⚖️

This BMJ analysis shows how the rise of orphan drugs and ATMPs is outpacing traditional HTA and reimbursement models, and argues for managed entry agreements, stronger patient engagement, and international collaboration to share risk and build real‑world evidence.

Read the full article to see practical policy options and what they mean for HEOR, pricing, and market access.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

Could hormone-based drugs rewrite the rules of obesity care?

A JAMA review shows GLP‑1 and GIP/GLP‑1 agonists (semaglutide ~15%, tirzepatide ~21% mean weight loss) are delivering substantial fat loss and cardiometabolic gains, while multi-receptor therapies and myostatin inhibitors aim to boost efficacy, preserve lean mass, and expand oral or less frequent dosing options. The piece also outlines trial evidence and the HEOR and market-access implications as these therapies shift treatment from symptom control to addressing underlying pathophysiology. 🔬

Read the full article to explore the data, pipeline candidates, and what this means for clinicians, payers, and patients.

#SyenzaNews #pharmaceuticals #HealthEconomics #costeffectiveness #MarketAccess

🚀 How can the NHS effectively balance emerging healthcare innovations with limited resources?

With the introduction of a unified framework for NICE NHS prioritization, we can expect strategic focus on critical areas like mental health, early cancer detection, and diabetes management. This approach aims to tackle pressing challenges while enhancing transparency and value-based decisions in resource allocation.

Curious about the implications of this pivotal change for the future of healthcare? Click to explore the full article!

#SyenzaNews #HealthcareInnovation #DigitalTransformation #resourceallocation

🫀 Are beta-blockers still a must-have for heart attack survivors with normal heart function?

Recent research from the New England Journal of Medicine reveals that for patients with preserved ejection fraction, these medications may not provide significant benefits in reducing risks like death or recurrent heart attacks. This pivotal meta-analysis encourages a reassessment of treatment protocols, suggesting that routine use of beta-blockers might not be necessary for all.

Dive deeper into these findings and learn how they could reshape post-myocardial infarction care.

#SyenzaNews #Healthcare #ClinicalTrials

Could a one-time CRISPR infusion change how we treat high cholesterol and triglycerides? 🧬

First-in-human Phase 1 data for CTX310 show nearly 50% LDL and ~55% triglyceride reductions after a single IV dose targeting ANGPTL3, with effects seen within two weeks and sustained to at least 60 days and no serious adverse events in this early cohort—signaling potential for durable, one-time cardiovascular risk reduction. The trial also highlights major HEOR and market-access implications if durability and broader safety are confirmed.

Read the full article to see the trial details, safety profile, and what this could mean for future lipid-care strategies.

#SyenzaNews #biotechnology #clinicaltrials #MarketAccess #costeffectiveness

🔍 Are we on the brink of a new era for treating neurofibromatosis type 1?

The recent approval of Koselugo (selumetinib) by the European Commission marks a transformative step in addressing the unmet medical needs of adult patients with inoperable plexiform neurofibromas. With the results from the KOMET Phase III trial highlighting a significant 20% objective response rate, this new oral treatment not only bridges a crucial gap but also provides hope for those previously limited to high-risk surgical interventions.

Explore the full implications of this groundbreaking approval and what it means for the future of NF1 management.

#SyenzaNews #pharmaceuticals #HealthcareInnovation

🌟 Are we on the brink of a breakthrough in obesity treatment?

A recent phase 2 trial of eloralintide, a novel amylin receptor agonist, showcased remarkable results, revealing significant weight loss of up to 20% in just 48 weeks! This groundbreaking treatment could reshape our approach to managing obesity and improve cardiometabolic health.

Dive into the full article to explore the implications of eloralintide’s efficacy, safety, and its potential to revolutionize obesity care. Your insights could be pivotal in this ever-evolving landscape!

#SyenzaNews #HealthcareInnovation #ClinicalTrials #HealthEconomics

Who decides whether you get a life‑saving kidney — and should patients be left out? 🤝

A JAMA commentary argues that boosting kidney transplant transparency by inviting patients or their representatives into local selection processes would rebuild trust, reduce inequities, and produce more patient-centered, cost‑effective outcomes amid a stark gap between the 92,739 on the waitlist and ~27,760 transplants performed annually. Practical steps—like recorded meetings, written input, or pilot trials—could align local practice with NASEM recommendations and improve HEOR measures.

Read the full article to see concrete reforms and why patient participation should be treated as a right, not a privilege.

#SyenzaNews #healthcare #HealthEconomics #healthcarepolicy #resourceallocation

Can regulatory reform really halve clinical trial approval times?

The MHRA’s risk-proportionate reforms — boosted by AI and digital platforms — cut average approvals from 91 to 41 days, speeding patient access to advanced therapies while keeping safety and oversight intact ⏱️🔬

Read the full analysis to understand the data, examples, and what this means for sponsors, HEOR and market access.

#SyenzaNews #clinicaltrials #regulatoryaffairs #DigitalTransformation #artificialintelligence

Can AI really cut hospital admissions and reclaim hundreds of clinician hours each year?

Philips’ Future Health Index 2025 shows South African professionals are strongly optimistic—91% expect fewer admissions and 94% see expanded capacity—while data-access delays cost clinicians roughly 187.5 hours annually 🩺. But a 17-point trust gap with patients means clinician-led education and rapid, equitable implementation are needed to turn promise into practice.

Read the full article to explore the stats, barriers, and policy pathways to harness AI for a more resilient South African health system.

#SyenzaNews #AIinHealthcare #HealthEconomics #DigitalTransformation #ai

Can South Africa’s private medical schemes break free from fee‑for‑service before costs spiral further? 🔎

The CMS Annual Report 2024/25 warns that FFS is driving expenditure above economic growth and highlights a shift toward capitation and risk‑transfer (managed care spend up 7.4%, with notable net gains from pharmacy capitation), while tariff reforms and the Draft Interim Block Exemption set the stage for value‑based payments and NHI alignment.

Read the full analysis to see the policy levers, HEOR implications, and practical steps market players can take to accelerate sustainable reimbursement models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #healthcarepolicy #costeffectiveness